Related Experiment Video
Updated: Sep 2, 2025
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
Genome Engineering for Next-Generation Cellular Immunotherapies
Jonathan J Park1,2,3,4,5, Kyoung A V Lee1,2,3,6, Stanley Z Lam1,2,3
1Department of Genetics, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06520, United States.
Abstract:
Over the past decade, cellular immunotherapies such as CAR-T, TCR-T, and NK cell therapies have achieved tremendous success in cancer treatment. However, various challenges and obstacles remain, including antigen escape, immunosuppression in the tumor microenvironment, toxicities, and on-target off-tumor effects. Recent strategies for overcoming these roadblocks have included the use of genome engineering. Multiplexed CRISPR-Cas and synthetic biology approaches facilitate the development of cell therapies with higher potency and sophisticated modular control; they also offer a toolkit for allogeneic therapy development. Engineering approaches have targeted genetic modifications to enhance long-term persistence through cytokine modulation, knockout of genes mediating immunosuppressive signals, and genes such as the endogenous TCR and MHC-I that elicit adverse host-graft interactions in an allogeneic context. Genome engineering approaches for other immune cell types are also being explored, such as CAR macrophages and CAR-NK cells. Future therapeutic development of cellular immunotherapies may also be guided by novel target discovery through unbiased CRISPR genetic screening approaches.
Insights
Genome engineering advances CAR-T, TCR-T, and NK cell therapies for cancer by overcoming challenges like antigen escape and improving allogeneic treatments. These sophisticated genetic tools enhance cell potency and control for better cancer immunotherapy outcomes.
Area of Science:
- Immunology
- Genetics
- Biotechnology
Background:
- Cellular immunotherapies like CAR-T, TCR-T, and NK cell therapies have shown success in cancer treatment.
- Challenges persist, including antigen escape, tumor microenvironment immunosuppression, toxicities, and off-tumor effects.
Purpose of the Study:
- To explore how genome engineering strategies can overcome current limitations in cellular immunotherapies.
- To highlight the role of CRISPR-Cas and synthetic biology in advancing cancer treatment.
Main Methods:
- Utilizing multiplexed CRISPR-Cas and synthetic biology for genetic modifications.
- Targeting genes for enhanced persistence, immunosuppression resistance, and allogeneic compatibility (e.g., TCR, MHC-I knockout).
- Exploring genome engineering for CAR macrophages and CAR-NK cells.
Main Results:
- Genome engineering enables enhanced potency and modular control of cell therapies.
- Strategies address antigen escape, immunosuppression, and host-graft interactions in allogeneic settings.
- Development of advanced cellular immunotherapies, including CAR macrophages and CAR-NK cells.
Conclusions:
- Genome engineering is crucial for overcoming challenges and improving the efficacy of cellular immunotherapies.
- CRISPR-Cas and synthetic biology offer powerful tools for next-generation cancer treatments.
- Future research may leverage unbiased CRISPR screening for novel immunotherapy target discovery.
Related Concept Videos
00:49What is Genetic Engineering?
01:29Microorganisms in Medicine and Therapeutics
00:59Gene Therapy